Attempt to Promote 1,016,000 Amphetamine Pills Thwarted in Taif    Saudi Fund for Development CEO Receives Sierra Leone's Foreign Minister    Public Investment Fund Launches "Savvy Gaming Group"    KSrelief Signs USD 10 Million Worth Agreement with UNICEF to Provide Basic Health Services for Mothers, Children in Yemen    Diriyah E-Prix 2-Time Champion Sam Bird Sets His Sight on More Triumph in 2022 Diriyah E-Prix    Asian Shares Mixed    [email protected]: Set to become world's technological and economic powerhouse    Royal Commission in Yanbu Achieves Arab Award for Operation and Maintenance    Minister of Islamic Affairs sponsors closing ceremony of 34th Virtual International Conference for Muslims of Latin America and Caribbean    IPA organizes 'Innovation and the Future of Government Work' conference on February 9    NDMC clears 43% of debts due for payment in 2022    Flying car cleared for takeoff, but you'll need a pilot's license    15% jump in number of Saudis working in private healthcare sector    Crown Prince, Chan-o-cha reaffirm need to open a new chapter in Saudi-Thai relations    Dozens feared lost as 'smuggling' boat capsizes off Florida    Netherlands to ease Covid restrictions despite rising case numbers    What the grand Republic Day parade means to India    Unvaccinated man denied heart transplant by Boston hospital    Deputy Ruler of Sharjah witnesses premiere of 'Narratives of the Place'    Sir Elton John postpones US shows after positive Covid-19 test    Bollywood's Shilpa Shetty cleared of obscenity over Richard Gere kiss    Egypt Records 1809 New Cases of COVID-19    Commerce Minister: Prime Minister of Thailand visit comes within Saudi Arabia's keenness to strengthen relations with countries of world    Minister of Justice Meets with His British Counterpart    Non-oil exports in Saudi Arabia increase by 26.1%    At least six killed in Cameroon stadium stampede    Al Hilal pays tribute to departing star striker Bafetimbi Gomis    Saudi Stock Exchange Main Index Ends Trading Higher at 12,108 Points    General Court of Audit President Inaugurates 8th Conference for Internal Audit with Int'l Participation    UN chief calls for Olympic Truce to build 'culture of peace' through power of sport    Taylor Swift slams Damon Albarn over songwriting comments    Australian Open: Peng Shuai T-shirt ban reversed after outcry    Cirque du Soleil to establish an academy and regional office in Saudi Arabia    Omani National Football Team Arrives in Jeddah to Meet Saudi National Team    'Bab Al Hara' Director Bassam AlMulla passes away at 65    Saudi Handball Team Loses to Qatar in Main Round of 2022 Asian Men's Handball Championship    Eighth Season of ABB FIA Formula E World Championship to kick off in Diriyah    Riyadh's Qualitative Events Enrich its Winter, Attract World Attention    SFDA: Fat is a Source of Energy and Its Abundance is Linked to Chronic Diseases    Reflections on celebration of Christmas    Royal Commission for AlUla to Hold Custodian of the Two Holy Mosques Endurance Cup 2022, Richard Mille AlUla Desert Polo    Saudi Arabia's Pavilion at Expo 2020 Dubai Organizes a Dance Theatrical Show for Children    Saudi Arabia rebuffs UN resolution on 'sexual orientation'    Kabir Khan eyes on joint Indian – Saudi film projects    Pilgrims Perform Dhuhr and Asr Prayers at Arafat Holy Site    Council of Senior Scholars: Muslim Brothers' Group Don't Represent Method of Islam, rather only Follows its Partisan Objectives, Violating our Graceful Religion    Eid Al-Adha Prayer Performed at the Grand Holy Mosque    Pilgrims Perform Dhuhr and Asr Prayers in Arafat Holy Site    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Pfizer seeks a nod for booster shot, works on new COVID-19 vaccine for Delta variant
Published in The Saudi Gazette on 09 - 07 - 2021

Drugmaker Pfizer said Thursday it is seeing waning immunity from its coronavirus vaccine and says it is picking up its efforts to develop a booster dose that will protect people from variants.
Pfizer said it would soon publish data about a third dose of vaccine and submit it to the US Food and Drug Administration, European Medicines Agency and other regulators. The company specified it would seek FDA emergency use authorization for a booster dose in August.
But in an unusual move, two top federal agencies said Americans don't need boosters yet and said it was not up to companies alone to decide when they might be needed.
Hours after Pfizer issued its statement, the FDA and Centers for Disease and Control issued a joint statement saying Americans do not need booster shots yet.
"Americans who have been fully vaccinated do not need a booster shot at this time," they said.
In a statement to CNN on Friday, the World Health Organization said, "We don't know whether booster vaccines will be needed to maintain protection against COVID-19 until additional data is collected," adding, "limited data available on how long the protection from current doses lasts and whether an additional booster dose would be beneficial and for whom."
Pfizer and its partner BioNTech said evidence was building that people's immunity starts to wane after they have been vaccinated. The Pfizer vaccine requires two doses to provide full immunity.
"As seen in real-world data released from the Israel Ministry of Health, vaccine efficacy in preventing both infection and symptomatic disease has declined six months post-vaccination, although efficacy in preventing serious illnesses remains high," Pfizer said in a statement.
"Additionally, during this period the Delta variant is becoming the dominant variant in Israel as well as many other countries. These findings are consistent with an ongoing analysis from the Companies' Phase 3 study," it added.
"While protection against severe disease remained high across the full six months, a decline in efficacy against symptomatic disease over time and the continued emergence of variants are expected.
Based on the totality of the data they have to date, Pfizer and BioNTech believe that a third dose may be beneficial within 6 to 12 months following the second dose to maintain highest levels of protection."
It gave no further details.
The announcement could have implications across the world. The Pfizer shot is the cornerstone of vaccination programs in many countries. Two-thirds of doses delivered across the European Union were made by Pfizer, according to the European Center. In Israel, Pfizer is the only vaccine used.
Of the 158 million fully vaccinated people in the US, more than half received the Pfizer shot.
US government officials have stressed that fully vaccinated people have a low risk of infection, even from the Delta or B.1.617.2 variant, which is more transmissible than earlier lineages of the virus.
Plus, several studies have indicated the mRNA vaccines made by Pfizer and Moderna confer long-term protection.
"FDA, CDC, and NIH (the National Institutes of Health) are engaged in a science-based, rigorous process to consider whether or when a booster might be necessary. This process takes into account laboratory data, clinical trial data, and cohort data -- which can include data from specific pharmaceutical companies, but does not rely on those data exclusively," they added.
It was a clear message to Pfizer, which has been hinting at the need for a booster shot for months.
"We continue to review any new data as it becomes available and will keep the public informed. We are prepared for booster doses if and when the science demonstrates that they are needed," the CDC and FDA said in the statement.
"The United States is fortunate to have highly effective vaccines that are widely available for those aged 12 and up. People who are fully vaccinated are protected from severe disease and death, including from the variants currently circulating in the country such as Delta," the statement continued.
"People who are not vaccinated remain at risk. Virtually all COVID-19 hospitalizations and deaths are among those who are unvaccinated. We encourage Americans who have not yet been vaccinated to get vaccinated as soon as possible to protect themselves and their community."
Israel's health ministry said in a statement earlier this week that it had seen the efficacy of Pfizer's vaccine drop from more than 90 percent to about 64 percent as the B.1.617.2 or Delta variant spread.
Pfizer said research showed booster doses of its vaccine, developed with BioNTech, produced levels of neutralizing antibodies that are five to 10 times higher than what's produced after two doses.
It said it's also developing a new formulation for a booster dose that may more thoroughly protect people from new variants.
"While Pfizer and BioNTech believe a third dose of BNT162b2 has the potential to preserve the highest levels of protective efficacy against all currently known variants including Delta, the companies are remaining vigilant and are developing an updated version of the Pfizer-BioNTech COVID-19 vaccine that targets the full spike protein of the Delta variant," the company said. Current vaccines target just a piece of the spike protein — the part of the virus it uses to attach to cells.
"The first batch of the mRNA for the trial has already been manufactured at BioNTech's facility in Mainz, Germany. The Companies anticipate the clinical studies to begin in August, subject to regulatory approvals." — CNN


Clic here to read the story from its source.